JP2014522868A - 精製タンパク質 - Google Patents

精製タンパク質 Download PDF

Info

Publication number
JP2014522868A
JP2014522868A JP2014523080A JP2014523080A JP2014522868A JP 2014522868 A JP2014522868 A JP 2014522868A JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014522868 A JP2014522868 A JP 2014522868A
Authority
JP
Japan
Prior art keywords
protein
preparation
less
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014522868A5 (cg-RX-API-DMAC7.html
Inventor
バーンズ,トーマス,エム
ホー,ジンジヤオ
ザービス−パパストートシス,グレゴリー
シヤーマー,エミリー,ベルチヤー
マクニール,ゲイリー,エル
ゴールデン,キヤスリン
Original Assignee
イレブン・バイオセラピユーテイクス・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イレブン・バイオセラピユーテイクス・インコーポレイテツド filed Critical イレブン・バイオセラピユーテイクス・インコーポレイテツド
Publication of JP2014522868A publication Critical patent/JP2014522868A/ja
Publication of JP2014522868A5 publication Critical patent/JP2014522868A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2014523080A 2011-07-29 2012-07-27 精製タンパク質 Pending JP2014522868A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161513453P 2011-07-29 2011-07-29
US61/513,453 2011-07-29
US201261591727P 2012-01-27 2012-01-27
US61/591,727 2012-01-27
PCT/US2012/048631 WO2013019652A1 (en) 2011-07-29 2012-07-27 Purified proteins

Publications (2)

Publication Number Publication Date
JP2014522868A true JP2014522868A (ja) 2014-09-08
JP2014522868A5 JP2014522868A5 (cg-RX-API-DMAC7.html) 2015-09-17

Family

ID=46682907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523080A Pending JP2014522868A (ja) 2011-07-29 2012-07-27 精製タンパク質

Country Status (10)

Country Link
US (1) US20140341843A1 (cg-RX-API-DMAC7.html)
EP (1) EP2736524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014522868A (cg-RX-API-DMAC7.html)
CN (1) CN104066439A (cg-RX-API-DMAC7.html)
AU (1) AU2012290379A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014002173A2 (cg-RX-API-DMAC7.html)
CA (1) CA2843197A1 (cg-RX-API-DMAC7.html)
RU (1) RU2014107743A (cg-RX-API-DMAC7.html)
SG (1) SG10201606218WA (cg-RX-API-DMAC7.html)
WO (1) WO2013019652A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533194A (ja) * 2014-10-23 2017-11-09 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド ペプチドバリアントを含む医薬組成物及びその使用方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
JP6450364B2 (ja) * 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
DK3461891T3 (da) * 2014-01-24 2020-08-10 Am-Pharma Bv Nedstrømsbehandling af en alkalisk phosphatase
WO2015138844A1 (en) * 2014-03-13 2015-09-17 Eleven Biotherapeutics, Inc. Methods for production of stable chimeric cytokine protein formulations in blow fill seal containers
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
CN104710527B (zh) * 2015-02-28 2018-08-24 苏州金盟生物技术有限公司 一种生物制品的内毒素去除方法
CN115598231B (zh) * 2016-08-15 2025-11-18 豪夫迈·罗氏有限公司 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
JPH02500562A (ja) * 1986-09-04 1990-03-01 イミュネックス・コーポレーション 組み換えインターロイキン‐1の精製
JPH05503007A (ja) * 1989-11-29 1993-05-27 アムジェン インコーポレーテッド 組み換えヒト・インターロイキン―1インヒビターの生産
JPH0776525A (ja) * 1988-03-09 1995-03-20 Otsuka Pharmaceut Co Ltd インターロイキン−1β組成物の安定化方法
JPH08504755A (ja) * 1992-09-17 1996-05-21 アムジェン ボールダー インコーポレイテッド インターロイキン−1インヒビターの薬学的処方物
JP2000512143A (ja) * 1996-06-07 2000-09-19 グルポ・レペチツト・エス・ピー・エイ 組換え大腸菌からのヒト・インターロイキン1レセプター・拮抗薬の精製方法
JP2006306890A (ja) * 1996-12-06 2006-11-09 Amgen Inc Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法
US20070082379A1 (en) * 2004-08-25 2007-04-12 Mizhou Hui Novel chimeric polypeptide and use thereof
JP2007531738A (ja) * 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド IL−1raの凝集を低下させる方法
JP2008521426A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド ドメイン抗体への複合体化により血清半減期が延長されたpladドメインペプチド
WO2011063195A2 (en) * 2009-11-20 2011-05-26 Dr. Reddy's Laboratories Ltd. Purification of modified cytokines
JP2013535204A (ja) * 2010-07-29 2013-09-12 イレブン・バイオセラピユーテイクス・インコーポレイテツド キメラil−1受容体1型アゴニストおよびアンタゴニスト

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2012103240A2 (en) * 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
JPH02500562A (ja) * 1986-09-04 1990-03-01 イミュネックス・コーポレーション 組み換えインターロイキン‐1の精製
JPH0776525A (ja) * 1988-03-09 1995-03-20 Otsuka Pharmaceut Co Ltd インターロイキン−1β組成物の安定化方法
JPH05503007A (ja) * 1989-11-29 1993-05-27 アムジェン インコーポレーテッド 組み換えヒト・インターロイキン―1インヒビターの生産
JPH08504755A (ja) * 1992-09-17 1996-05-21 アムジェン ボールダー インコーポレイテッド インターロイキン−1インヒビターの薬学的処方物
JP2000512143A (ja) * 1996-06-07 2000-09-19 グルポ・レペチツト・エス・ピー・エイ 組換え大腸菌からのヒト・インターロイキン1レセプター・拮抗薬の精製方法
JP2006306890A (ja) * 1996-12-06 2006-11-09 Amgen Inc Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法
JP2007531738A (ja) * 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド IL−1raの凝集を低下させる方法
US20070082379A1 (en) * 2004-08-25 2007-04-12 Mizhou Hui Novel chimeric polypeptide and use thereof
JP2008521426A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド ドメイン抗体への複合体化により血清半減期が延長されたpladドメインペプチド
WO2011063195A2 (en) * 2009-11-20 2011-05-26 Dr. Reddy's Laboratories Ltd. Purification of modified cytokines
JP2013535204A (ja) * 2010-07-29 2013-09-12 イレブン・バイオセラピユーテイクス・インコーポレイテツド キメラil−1受容体1型アゴニストおよびアンタゴニスト

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5014009336; ERIC S FURFINE: 'EBI-006: AN IL-1 RECEPTOR INHIBITOR DESIGNED FOR THE TREATMENT OF DRY EYE SYNDROME' [ONLINE] , 20120507, P1 *
JPN6015030103; Cellular Immunology Vol.169, 1996, p.226-237 *
JPN6016017049; J. Biol. Chem. 286(49)(2011.12), p.42594-602 *
JPN6016017056; Immunology 77(1992), p.235-244 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533194A (ja) * 2014-10-23 2017-11-09 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド ペプチドバリアントを含む医薬組成物及びその使用方法

Also Published As

Publication number Publication date
AU2012290379A1 (en) 2014-02-06
EP2736524A1 (en) 2014-06-04
WO2013019652A1 (en) 2013-02-07
RU2014107743A (ru) 2015-09-10
CA2843197A1 (en) 2013-02-07
CN104066439A (zh) 2014-09-24
BR112014002173A2 (pt) 2017-03-01
SG10201606218WA (en) 2016-09-29
US20140341843A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
JP6030554B2 (ja) キメラil−1受容体1型アゴニストおよびアンタゴニスト
US20140341843A1 (en) Purified proteins
WO2012103240A2 (en) Receptor binding agents
TWI691512B (zh) Fc融合高親和性IgE受體α鏈
EP1723173A1 (en) Il-4/il-13 sepecific polypetides and therapeutic uses thereof
CN118598975A (zh) 白介素-21突变体及其应用
CN104394881A (zh) 修饰的人肿瘤坏死因子受体-1多肽的新用途
CN114621353B (zh) 一种重组融合蛋白及其应用
TWI586803B (zh) 嵌合介白素-1(il-1)受體型i拮抗劑
HK1181778B (en) Chimeric il-1 receptor type i agonists and antagonists
HK1181778A (en) Chimeric il-1 receptor type i agonists and antagonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161220